

**PION Antibody**  
**Catalog # ASC11271****Specification****PION Antibody - Product Information**

Application	WB, IHC-P, IF, E
Primary Accession	<a href="#">A4D1B5</a>
Other Accession	<a href="#">NP_059135, 54103</a>
Reactivity	Human, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Application Notes	PION antibody can be used for detection of PION by Western blot at 0.25 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL.

**PION Antibody - Additional Information****Gene ID** 54103**Target/Specificity**

PION antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human PION. The immunogen is located within amino acids 770 - 820 of PION.

**Reconstitution & Storage**

PION antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

**Precautions**

PION Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**PION Antibody - Protein Information****Name** GSAP**Synonyms** PION**Function**

Regulator of gamma-secretase activity, which specifically activates the production of amyloid-beta protein (amyloid-beta protein 40 and amyloid-beta protein 42), without affecting the cleavage of other gamma-secretase targets such as Notch. The gamma-secretase complex is an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). Specifically promotes the gamma-cleavage of APP CTF-alpha (also named APP-CTF) by the gamma-secretase complex to generate amyloid-beta, while it reduces the epsilon-cleavage of APP CTF-alpha, leading to a low production of AICD.

**Cellular Location**

Golgi apparatus, trans-Golgi network


**Tissue Location**

Widely expressed..

**PION Antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**PION Antibody - Images**

Western blot analysis of IRF3 in (A) human kidney and (B) rat kidney lysate with IRF3 antibody at 1 µg/mL..

**PION Antibody - Background**

PION Antibody: Accumulation of the amyloid-beta peptide (Abeta) in the cerebral cortex is a critical event in the pathogenesis of Alzheimer's disease. The beta-amyloid protein precursor (APP) is cleaved by one of two beta-secretases (BACE and BACE2), producing a soluble derivative of the protein and a membrane anchored 99 -amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for gamma-secretase to generate the 4 kDa amyloid-beta peptide (Abeta), which is deposited in the Alzheimer's disease patient's brains. PION, or GSAP, selectively increases amyloid-beta production through a mechanism involving its interaction with both gamma-secretase and the APP C-terminal fragment, suggesting that PION may be a potential therapeutic target for the treatment of Alzheimer's disease.

**PION Antibody - References**

Ponte P, Gonzalez-DeWhitt P, Schilling J, et al. A new A4 amyloid mRNA contains a domain homologous to serine proteinase inhibitors. *Nature* 1988; 331:525-77.  
Selkoe DJ. Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. *Annu. Rev. Cell Biol.* 1994; 10:373-403.  
He G, Luo W, Li P, et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. *Nature* 2010; 467:95-9.